Protocol
Growth Hormone
MK-677 (Ibutamoren) Research Protocol [2026]
Oral ghrelin receptor agonism for GH and IGF-1 elevation without injection requirement.
Compounds
Protocol Phases
Initiation
Weeks 1 to 4
10 mg orally at night. Evening dosing aligns with natural GH pulsatility and reduces water retention experienced with AM dosing by some subjects.
Escalation
Weeks 5 to 12
20 to 25 mg orally at night. Most research protocols cap at 25 mg. Higher doses produce minimal additional GH response with increased appetite and water retention side effects.
FAQ
How does MK-677 compare to CJC-1295 and Ipamorelin?
MK-677 is an oral compound and requires no injection. It acts as a ghrelin mimetic, directly triggering GH release at the pituitary. CJC-1295 plus Ipamorelin acts through GHRH and ghrelin pathways via injection for a cleaner, more pulsatile GH release. MK-677 produces more sustained GH elevation which also causes more cortisol and prolactin elevation than pulsatile injection protocols.
Why is MK-677 taken at night?
The largest natural GH pulse occurs during deep sleep. Taking MK-677 1 to 2 hours before sleep aligns the peak drug effect with this window. Evening dosing is also consistently associated with less daytime water retention and hunger compared to morning dosing.
Does MK-677 cause water retention?
Yes. Water retention is the most common and significant side effect, particularly in the first 2 to 4 weeks and at doses above 15 mg. It is typically mild and transient. Reducing sodium intake helps manage this effect. If significant edema develops, dose reduction is recommended.
Can MK-677 be stacked with CJC-1295 and Ipamorelin?
Some research protocols combine MK-677 with injectable GH peptides. The combination provides continuous GH support from MK-677 plus pulsatile peaks from the injectable stack. However, the combination significantly increases appetite, water retention, and lethargy risk and requires careful dose management.
Research Notes
- MK-677 is an oral compound. It does not require reconstitution or injection.
- Caloric intake increases substantially on MK-677. Track intake to avoid unintended caloric surplus.
- Cycle 12 to 16 weeks maximum then take an equivalent break before resuming.
Related Protocols
For research use only. Not medical advice.